Letter to the Editor
In vitro potency of amikacin against carbapenem-resistant Pseudomonas aeruginosa: A target for nebulization strategy?
Gabriel T. Cubaa,b,1,
, Paulo H.D. Santosa,1, Antonio C.C. Pignataria, David P. Nicolauc, Carlos R.V. Kiffera
Corresponding author
a Universidade Federal de São Paulo (UNIFESP), Escola Paulista de Medicina, São Paulo, SP, Brazil
b Universidade de São Paulo (HCFMUSP), Hospital das Clínicas, Faculdade de Medicina, São Paulo, SP, Brazil
c Center of Anti-infective Research and Development, Hartford Hospital, Hartford, CT, United States
Read
2996
Timeswas read the article
1394
Total PDF
1602
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2025 6 | 38 | 27 | 65 |
| 2025 5 | 72 | 56 | 128 |
| 2025 4 | 45 | 38 | 83 |
| 2025 3 | 51 | 39 | 90 |
| 2025 2 | 40 | 43 | 83 |
| 2025 1 | 39 | 34 | 73 |
| 2024 12 | 35 | 33 | 68 |
| 2024 11 | 37 | 35 | 72 |
| 2024 10 | 27 | 35 | 62 |
| 2024 9 | 35 | 28 | 63 |
| 2024 8 | 47 | 33 | 80 |
| 2024 7 | 45 | 32 | 77 |
| 2024 6 | 42 | 34 | 76 |
| 2024 5 | 35 | 36 | 71 |
| 2024 4 | 41 | 31 | 72 |
| 2024 3 | 35 | 31 | 66 |
| 2024 2 | 40 | 33 | 73 |
| 2024 1 | 28 | 36 | 64 |
| 2023 12 | 26 | 37 | 63 |
| 2023 11 | 48 | 47 | 95 |
| 2023 10 | 35 | 46 | 81 |
| 2023 9 | 46 | 54 | 100 |
| 2023 8 | 30 | 32 | 62 |
| 2023 7 | 25 | 28 | 53 |
| 2023 6 | 25 | 14 | 39 |
| 2023 5 | 35 | 33 | 68 |
| 2023 4 | 27 | 22 | 49 |
| 2023 3 | 58 | 36 | 94 |
| 2023 2 | 41 | 36 | 77 |
| 2023 1 | 36 | 25 | 61 |
| 2022 12 | 65 | 33 | 98 |
| 2022 11 | 59 | 54 | 113 |
| 2022 10 | 54 | 36 | 90 |
| 2022 9 | 36 | 41 | 77 |
| 2022 8 | 42 | 43 | 85 |
| 2022 7 | 36 | 34 | 70 |
| 2022 6 | 80 | 54 | 134 |
| 2022 5 | 63 | 49 | 112 |
| 2022 4 | 3 | 6 | 9 |
Show all
